TRAVOPROST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Travoprost, and when can generic versions of Travoprost launch?
Travoprost is a drug marketed by Alembic, Apotex, Chartwell Rx, Gland Pharma Ltd, Lupin Ltd, Micro Labs, Mylan, and Somerset Theraps Llc. and is included in eight NDAs.
The generic ingredient in TRAVOPROST is travoprost. There are fifteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the travoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Travoprost
A generic version of TRAVOPROST was approved as travoprost by CHARTWELL RX on March 1st, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRAVOPROST?
- What are the global sales for TRAVOPROST?
- What is Average Wholesale Price for TRAVOPROST?
Summary for TRAVOPROST
See drug prices for TRAVOPROST
Recent Clinical Trials for TRAVOPROST
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Salus University | Phase 4 |
| Assiut University | Phase 4 |
| Glaukos Corporation | Phase 3 |
Pharmacology for TRAVOPROST
| Drug Class | Prostaglandin Analog |
Medical Subject Heading (MeSH) Categories for TRAVOPROST
Anatomical Therapeutic Chemical (ATC) Classes for TRAVOPROST
Paragraph IV (Patent) Challenges for TRAVOPROST
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| IZBA | Ophthalmic Solution | travoprost | 0.003% | 204822 | 1 | 2015-12-30 |
| TRAVATAN Z | Ophthalmic Solution | travoprost | 0.004% | 021994 | 1 | 2009-02-19 |
| TRAVATAN | Ophthalmic Solution | travoprost | 0.004% | 021257 | 1 | 2008-11-28 |
US Patents and Regulatory Information for TRAVOPROST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 210458-001 | Dec 20, 2019 | AT1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 205050-001 | Jul 7, 2017 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Gland Pharma Ltd | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 218159-001 | Jul 12, 2024 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Somerset Theraps Llc | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 217228-001 | Sep 23, 2024 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 203431-001 | Jul 10, 2015 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 091340-001 | Mar 1, 2013 | AT1 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for TRAVOPROST
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Izba | travoprost | EMEA/H/C/002738 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma. |
Authorised | no | no | no | 2014-02-20 | |
| Novartis Europharm Limited | Travatan | travoprost | EMEA/H/C/000390 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1). |
Authorised | no | no | no | 2001-11-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
